

Annex D – Post-Class Period Exhibits Challenged in Opposition

Exhibit No.	Description	Cited in MTD	Bases for Court's Consideration
56	Press Release – “AstraZeneca COVID-19 vaccine authorised for emergency use by the World Health Organization” (Feb. 15, 2021)	Pgs. 4, 13, 21, 25	<ul style="list-style-type: none"> Cited for WHO approval of AZD1222 for those aged 18+, which is judicially noticeable, undisputed, and acknowledged in the Opp. at nn.20, 37 Cited for AZ’s stated commitment to equitable distribution and no-profit from AZD1222 during pandemic, which is undisputed and acknowledged in the AC, ¶¶ 36, 38, 47, 60, 61, and Opp. at 3-4 & n.5
58	“Germany Approves AstraZeneca for over-65s, extends gap between doses,” <i>Reuters</i> (Mar. 4, 2021)	Pgs. 21, 34	<ul style="list-style-type: none"> Cited for German regulators’ approval of AZD1222 for those aged 65+, which is judicially noticeable, undisputed, and acknowledged in the Opp. at nn.20, 37
60	Press Release – “Update following statement by NIAID on AZD1222 US Phase III trial data” (Mar. 23, 2021)	Pg. 14	<ul style="list-style-type: none"> Cited for DSMB response to AZD1222 trial data, which is judicially noticeable, undisputed, and referenced in the AC, ¶¶ 129-130
62	AstraZeneca PLC (AZN) CEO Pascal Soriot on Q2 2021 Results – Earnings Call Transcript (Aug. 1, 2021)	Pgs. 4, 14, 25	<ul style="list-style-type: none"> Cited for AZ’s stated commitment to equitable distribution of AZD1222, which is undisputed and acknowledged in the AC, ¶¶ 38, 47, 60, 61 and Opp. at n.5
63	Press Release – “Oxford vaccine reaches one billion doses released” (July 29, 2021)	Pgs. 14, 31	<ul style="list-style-type: none"> Cited for number of AZD1222 doses released, which is undisputed and acknowledged in the Opp at nn.20, 37 Cited for AZ’s stated commitment to equitable distribution, which is undisputed and acknowledged in the AC, ¶¶ 38, 47, 60, 61, and Opp. at n.5
64	Pascal Soriot Bloomberg Interview Transcript (July 29, 2021)	Pg. 14	<ul style="list-style-type: none"> Cited for recognition that three COVID-19 vaccines had already received FDA EUA approval, which is judicially noticeable, undisputed, and acknowledged in the Opp. at 2 & n.20

Exhibit No.	Description	Cited in MTD	Bases for Court's Consideration
			<ul style="list-style-type: none"> • Cited for AZ's disclosure that it would not seek FDA EUA and would instead seek full regulatory approval, which is undisputed and acknowledged in the Opp. at Ex. A
65	“AstraZeneca coronavirus vaccine sales triple, but US plans delayed again,” <i>The National</i> (July 29, 2021)	Pg. 14	<ul style="list-style-type: none"> • Cited for recognition that three COVID-19 vaccines had already received FDA EUA approval, which is judicially noticeable, undisputed, and acknowledged in the Opp. at 2 & n.20 • Cited for AZ's disclosure that it would not seek FDA EUA and would instead seek full regulatory approval, which is undisputed and acknowledged in the Opp. at Ex. A
66	FDA News Release – “FDA Approves First Covid-19 Vaccine” (Aug. 23, 2021)	Pg. 14	<ul style="list-style-type: none"> • Cited for FDA approval of Pfizer-BioNTech COVID-19 vaccine, which is judicially noticeable and undisputed
67	“Tracking Coronavirus Vaccinations Around the World,” <i>The New York Times</i> (as of Sept. 27, 2021)	Pg. 14	<ul style="list-style-type: none"> • Cited for use of AZD1222 globally, which is judicially noticeable, undisputed, and acknowledged in the Opp. at nn.20, 37